顺铂和5-氟脲嘧啶联合尼妥珠单抗作为一线方案治疗转移鼻咽癌的临床观察  

Clinical Observation of Cisplatin and 5-fluorouracil Combined with Nimotuzumab as First-line Therapy for Metastatic Nasopharyngeal Carcinoma

作　　者：舒禹先[1] 

机构地区：[1]江西省肿瘤医院,330029

出　　处：《实用癌症杂志》2016年第12期2090-2092,共3页The Practical Journal of Cancer

摘　　要：目的探究顺铂和5-氟尿嘧啶联合尼妥珠单抗作为一线方案治疗转移鼻咽癌的临床疗效及安全性。方法将50例鼻咽癌转移患者随机分成对照组和实验组,对照组患者采用顺铂和5-氟尿嘧啶治疗,实验组患者采用顺铂和5-氟尿嘧啶联合尼妥珠单抗治疗,比较2组患者近期治疗有效率、控制率及不良反应发生情况。结果实验组患者CR及PR均明显高于对照组,PD明显低于对照组,差异均有统计学意义(P<0.05);实验组患者的治疗有效率及控制率分别为72.0%、92.0%,均明显高于对照组患者(44.0%、72.0%),且有统计学差异(P<0.05)。2组患者均有明显的不良反应发生,但每种不良反应相比均无明显的统计学差异(P>0.05)。实验组患者1年生存率为92.0%,明显高于对照组患者72.0%(P<0.05)。结论采用顺铂和5-氟尿嘧啶联合尼妥珠单抗作为一线方案治疗鼻咽癌转移可以显著提高治疗有效率、控制率及1年生存率,且不会增加不良反应发生率,是1种更为可取的治疗方案。Objective To explore the clinical efficacy and safety of cisplatin and 5-fluorouracil combined with nimotuzumab as first-line treatment for metastatic nasopharyngeal carcinoma. Methods 50 cases of metastatic nasopharyngeal carcinoma were randomly divided into the control group and the experimental group, each with 25 cases. The control group were treated with cisplatin and 5-fluorouracil therapy, the experimental group were treated with cisplatin and 5-fluorouracil combined with nimotu- zumab treatment,treatment efficiency, control rates and adverse events of the 2 groups were compared. Results CR and PR in the experimental group were significantly higher than those of the control group, PD were significantly lower than that of the control group （ P 〈 0.05 ） ; There were no statistically significant differences in adverse reactions between the 2 groups （ P 〉 0.05 ）. 1-year survival rate of the experimental group was 92.0%, which was significantly high than that of the control group, 72.0% （ P 〈 0.05）. Conclusion Cisplatin and 5-fluorouracil combined with nimotuzumab as first-line treatment for metastatic nasopharyngeal carcinoma can significantly improve treatment efficiency, control rate, and 1-year survival rate without increasing adverse reactions. It is a more preferable treatment regimen.

关 键 词：顺铂 5-氟尿嘧啶 尼妥珠单抗 转移鼻咽癌 临床疗效 安全性 

分 类 号：R739.63[医药卫生—肿瘤]